Table 3. Recipient Characteristics.
| Track 2 N = 23 | Track 3 N = 12 | P Value± | |
|---|---|---|---|
| Age * | 61 (21.5) | 50.5 (11.25) | 0.054 |
| Sex | 0.16 | ||
| Male | 39.1% | 66.7% | |
| Female | 60.9% | 33.3% | |
| BMI * | 29.9 (12.06) | 27.3 (6.68) | 0.96 |
| Race | 0.84 | ||
| Caucasian | 17.4% | 25.0% | |
| African American | 4.3% | 8.3% | |
| Hispanic | 60.9% | 58.3% | |
| Asian | 17.4% | 8.3% | |
| Days from symptom onset to treatment * | 10 (10.5) | 16 (9.5) | 0.0063 |
| Day 10 COVID swab PCR^ | 0.6 | ||
| Positive | 54.5% | 10.0% | |
| Negative | 45.5% | 30.0% | |
| Not Determined | 60.0% | ||
| Day 30 survival status | 0.015 | ||
| Alive | 82.6% | 58.3% | |
| Fatal | 17.4% | 41.7% | |
| Intubated after treatment | |||
| Yes | 17.4% | NA | |
| No | 82.6% | NA | |
| Days from infusion to discharge or death * | 8 (9) | 10 (7) | 0.062 |
| Developed ARDS | 52.2% | 100% | 0.0055 |
| Developed End Organ Dysfunction | 21.7% | 50.0% | 0.13 |
| Concomitant Treatment | |||
| Hydroxychloroquine | 69.6% | 91.7% | 0.22 |
| Azithromycin | 52.2% | 75% | 0.28 |
| Doxycycline or other antibiotic | 56.5% | 50% | 0.74 |
| Steroids | 52.2% | 100% | 0.0055 |
| Tociluzumab | 17.4% | 58.3% | 0.022 |
| Remdesivir | 4.3% | 8.3% | 1 |
| Comorbidities | |||
| Hypertension | 47.8% | 33.3% | 0.49 |
| Diabetes | 34.8% | 50.0% | 0.48 |
| Heart Failure or CAD | 4.3% | 0% | 1 |
| History of Smoking | 17.4% | 16.7% | 0.51 |
| Lung disease or Asthma | 26.1% | 8.3% | 0.38 |
| Immunocompromised | 30.4% | 8.3% | 0.22 |
| Active Cancer | 26.1% | 8.3% | 0.38 |
*Median (IQR)
^Track 2, n = 22; Track 3, n = 10
±Continuous variables were analyzed using T-test; Categorical values were analyzed using Fisher’s exact test